Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, Rolf Kaiser, Anders Mellemgaard et al. · The Lancet Oncology · 2014

Cited by 950 works. doi:10.1016/s1470-2045(13)70586-2

Authors

References